Additional information
| Trade Name | HALAVEN |
|---|---|
| Generic Name | ERIBULIN MESYLATE |
| Manufacturer | Elsai |
| Drug Type | Oncology |
| Indication | Breast Cancer |
| Doasage Form | Injectible |
| Packaging | 0.5mg/ml |
HALAVEN (Eribulin Mesylate)-2ml
HALAVEN (Eribulin Mesylate) is an “antineoplastic” or “cytotoxic” chemotherapy drug, classified as a “non-taxane microtubule inhibitor”. Antimicrotubule agents, attack cells during a certain phase of division and so are considered cell-cycle specific. They attack cell’s apparatus for dividing and reproducing itself ultimately results in cell death.
Halaven is used for the treatment of patients with
- metastatic breast cancer (mBC).
- unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
